Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…
9,549€
1,63%
Echtzeit-Aktienkurs Intellia Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Intellia Therapeutics Inc. Aktie
Is Intellia Therapeutics Stock a Buy Now?
The companys future will depend on its innovative qualities.…
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials.…